Gilead’s new HIV prevention drug lenacapavir will ‘change the face of HIV,’ says CEO Daniel O’Day
Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...
Gilead and LEO Pharma link on programmes for inflammatory conditions
Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...
Contract Pharma2h
Gilead, LEO Pharma Partner to Accelerate Development of Oral STAT6 Program
Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small ...
Gilead CEO Daniel O'Day on new HIV prevention medicine: It's going to change the face of HIV
CNBC’s Angelica Peebles and Gilead chairman and CEO Daniel O’Day join 'Squawk Box' to discuss the company's new HIV ...
After UnitedHealthcare CEO's killing, San Francisco beefs up security around biotech's J.P. Morgan Healthcare Conference
San Francisco and its hotel industry are partnering to beef up security around this week's 43rd annual J.P. Morgan Healthcare ...
bovnews3h
Gilead Sciences Inc (GILD) Reported a 37.45% Operating Margin Last Year—What’s the Real Story?
Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $89.88 which represents a slight increase of $0.74 or 0.83% from the prior close of $89.14. The stock opened at $90.19 and ...
BioSpace3h
Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO
Gilead’s potential investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor ...
The Macomb Daily3h
Macomb mom collaborates on children’s book for breast cancer families
The colorful picture book is helping parents of young children deal with the difficult journey that follows a breast cancer ...
Gilead Sciences: Supreme Court Case and New Innovations Drive Buy Rating
Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...
Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases
Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic ...
ENDPOINTS NEWS5h
Gilead taps in­to STAT6 space via $250M deal with Leo Phar­ma
Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...
The Pharma Letter6h
Gilead partners with LEO Pharma on oral STAT6 program
Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside ...